Deep radiomic prediction with clinical predictors of the survival in patients with rheumatoid arthritis-associated interstitial lung diseases

2018 ◽  
Author(s):  
Hiroyuki Yoshida ◽  
Janne Nappi ◽  
Radin Nasirudina ◽  
Chinatsu Watari ◽  
Shoji Kido ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Lung Diseases ◽  
Interstitial Lung Diseases ◽  
Clinical Predictors

scholarly journals The Extent and Diverse Trajectories of Longitudinal Changes in Rheumatoid Arthritis Interstitial Lung Diseases Using Quantitative HRCT Scores

2021 ◽  
Vol 10 (17) ◽  
pp. 3812
Author(s):  
Jeong Seok Lee ◽  
Grace-Hyun J Kim ◽  
You-Jung Ha ◽  
Eun Ha Kang ◽  
Yun Jong Lee ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Lung Diseases ◽  
Disease Duration ◽  
Single Point ◽  
Ground Glass Opacity ◽  
Interstitial Lung Diseases ◽  
High Resolution Computed Tomography ◽  
Baseline Serum ◽  
Longitudinal Changes ◽  
Point Increase

We aimed to validate quantitative high-resolution computed tomography (HRCT) imaging analyses of interstitial lung disease (ILD) in rheumatoid arthritis (RA) patients, and to delineate a broad spectrum of annual longitudinal changes of ILD severity in the RA-ILD cohorts. Retrospective cohort 1 (n = 26) had matched PFT results and prospective cohort 2 (n = 34) were followed for over two years with baseline serum specimen. Automated quantitative analysis of HRCT was expressed as the extent of ground-glass opacity, lung fibrosis, honeycombing, and their summation—the total extent of quantitative ILD (QILD). Higher QILD score was associated with lower pulmonary function especially for DLCO% (ρ = −0.433, p = 0.027). Higher serum level of Krebs von den Lungen 6 were significantly associated with high QILD scores (ρ = 0.400, p = 0.026). Regarding QILD score changes in whole lung, even a single point increase was significantly associated with interval progression detected by the radiologist. Four distinct patterns (improvement, worsening, convex-like, and concave-like) during the 24 months were described by QILD scores. Prolonged disease duration of ILD at baseline was significantly associated with worsening of QILD scores. QILD has the potential to reliably evaluate the dynamic severity changes in patients with RA-ILD.

scholarly journals Clinical Characteristics and Predictors of the Recurrence of Organising Pneumonia Associated with Rheumatoid Arthritis

2020 ◽  
Author(s):  
Ryosuke Kamei ◽  
HIROYUKI YAMASHITA ◽  
Yuko Takahashi ◽  
Hiroshi Kaneko
Keyword(s):  
Rheumatoid Arthritis ◽  
Lung Diseases ◽  
Clinical Characteristics ◽  
Recurrence Risk ◽  
Interstitial Lung Diseases ◽  
High Recurrence Rate ◽  
Free Survival ◽  
First Recurrence ◽  
Study Participants ◽  
The Relationship

Abstract Background: Organizing pneumonia (OP) accounts for ~10% of the interstitial lung diseases in patients diagnosed with rheumatoid arthritis (RA). There are only a few published studies that have described RA-associated OP (RA–OP), each with comparatively few study participants. Furthermore, despite the high frequency of secondary flareups, no studies to date have identified factors that predict RA–OP recurrence. This study aimed to clarify the clinical characteristics of RA–OP, to determine the relationship between OP and RA exacerbations, and to identify predictors of RA–OP disease recurrence.Methods: The data of 33 patients with RA–OP admitted to our hospital between 2006 and 2016 were retrospectively analysed.Results: RA onset preceded OP in 82% of patients; OP preceded or co-occurred with RA in 9% each. The median [Q1, Q3] age at first OP onset was 64.0 [55.0, 68.0] years and 5.5 [1.0, 19.3] years after RA onset. At OP onset, 42% of events exhibited unilateral shadows and 76% had normal KL-6; RA disease control remained good in 52% and was exacerbate d in only 18%. Ten (30%) patients experienced OP recurrence with an interval of 13.0 [7.5, 22.5] months between events, with a rate of first recurrence of 127 per 1,000 person-years. Compared with 14 non-recurrent cases, 10 recurrent cases showed lower age at first OP (59.5 years vs. 67.1 years; p = 0.043) and shorter period from RA to first OP (6.4 vs. 14.2 years; p = 0.047) and included more OP-preceding patients (30% vs. 0%; p = 0.029) and more ever-smokers (80% vs. 36%; p = 0.032). OP-preceding patients showed shorter median recurrence-free survival time (15 vs. 136 months; p = 0.009) and higher recurrence risk (hazard ratio, 5.5; p = 0.021). Conclusions: RA–OP showed a high recurrence rate but no association with RA exacerbation. Four predictors of RA–OP recurrence were identified.

Innate immunity alterations in idiopathic interstitial pneumonias and rheumatoid arthritis-associated interstitial lung diseases

2015 ◽  
Vol 163 (2) ◽  
pp. 179-186 ◽  
Author(s):  
Ilias C. Papanikolaou ◽  
Kyriaki A. Boki ◽  
Evangelos J. Giamarellos-Bourboulis ◽  
Antigoni Kotsaki ◽  
Konstantinos Kagouridis ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Innate Immunity ◽  
Lung Diseases ◽  
Interstitial Lung Diseases ◽  
Idiopathic Interstitial Pneumonias

scholarly journals Diagnosis, Clinical Features and Management of Interstitial Lung Diseases in Rheumatic Disorders: Still a Long Journey

2022 ◽  
Vol 11 (2) ◽  
pp. 410
Author(s):  
Marco Sebastiani ◽  
Caterina Vacchi ◽  
Giulia Cassone ◽  
Andreina Manfredi
Keyword(s):  
Rheumatoid Arthritis ◽  
Interstitial Lung Disease ◽  
Connective Tissue ◽  
Lung Disease ◽  
Clinical Features ◽  
Lung Diseases ◽  
Connective Tissue Diseases ◽  
Interstitial Lung Diseases ◽  
Pulmonary Complications ◽  
Autoimmune Rheumatic Diseases

Interstitial lung disease (ILD) is one of the most frequent pulmonary complications of autoimmune rheumatic diseases (ARDs), and it is mainly associated with connective tissue diseases (CTDs) and rheumatoid arthritis (RA) [...]

Risk factors of interstitial lung diseases in patients with rheumatoid arthritis

2019 ◽  
Author(s):  
Elena Klester ◽  
Karolina Klester ◽  
Yakov Shoykhet ◽  
Valeriy Elykomov ◽  
Valentina Yarkova ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Risk Factors ◽  
Lung Diseases ◽  
Interstitial Lung Diseases

scholarly journals Adalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis

2014 ◽  
Vol 40 (1) ◽  
pp. 77-81 ◽  
Author(s):  
Olivia Meira Dias ◽  
Daniel Antunes Silva Pereira ◽  
Bruno Guedes Baldi ◽  
Andre Nathan Costa ◽  
Rodrigo Abensur Athanazio ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Interstitial Lung Disease ◽  
Autoimmune Diseases ◽  
Lung Diseases ◽  
Fungal Infections ◽  
Interstitial Lung Diseases ◽  
Pulmonary Complications ◽  
First Case ◽  
Increased Risk ◽  
History Of

The use of immunobiological agents for the treatment of autoimmune diseases is increasing in medical practice. Anti-TNF therapies have been increasingly used in refractory autoimmune diseases, especially rheumatoid arthritis, with promising results. However, the use of such therapies has been associated with an increased risk of developing other autoimmune diseases. In addition, the use of anti-TNF agents can cause pulmonary complications, such as reactivation of mycobacterial and fungal infections, as well as sarcoidosis and other interstitial lung diseases (ILDs). There is evidence of an association between ILD and the use of anti-TNF agents, etanercept and infliximab in particular. Adalimumab is the newest drug in this class, and some authors have suggested that its use might induce or exacerbate preexisting ILDs. In this study, we report the first case of acute ILD secondary to the use of adalimumab in Brazil, in a patient with rheumatoid arthritis and without a history of ILD.

Sign in / Sign up

Export Citation Format

Share Document